CASI Pharmaceuticals Granted Extension by Nasdaq to Meet Listing Requirements

CASI Pharmaceuticals has received an extension from the Nasdaq Hearings Panel to regain compliance with the Market Value of Listed Securities (MVLS) Rule 5550(b)(2) by February 17, 2026. The company was initially notified on May 5, 2025, that its MVLS had fallen below the minimum requirement of $35 million. The extension was granted after the Panel reviewed CASI's recent actions, including appointing new leadership, focusing on CID-103 development, securing financing, and planning the divestiture of China assets. CASI is committed to regaining compliance and is developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. The company is also conducting Phase 1 studies for CID-103 in renal allograft rejection and immune thrombocytopenia. CASI acknowledges the risks and uncertainties associated with its business, including potential delisting, financing needs, and product development, and will take necessary actions to meet Nasdaq's requirements.